Ohio State Navbar


Kamalakannan Palanichamy, PhD.


Dr. Kamalakannan Palanichamy, PhD
Assistant Professor

410 W. 12th Ave
Columbus, OH 43210

Ph: 614-685-4245

Email: Kamalakannan.Palanichamy@osumc.edu



Research Area 

   My research focus is to bridge the gap between basic and clinical research. To this end, we explore transcriptomic, epigenetic, metabolomic, proteomic and genomic profiles in patient tumor biopsy samples to identify predictive and prognostic markers with a view to identify and validate therapeutic targets. We are also working to identify the underlying mechanisms of chemo and radiation resistance in treatment refractory tumors by short-circuiting signal transduction pathways and determining the mutational status, gene and molecular signatures mediating treatment resistance. We have developed cancer stem cell models to investigate cancer stem cell biology via protein-protein interactions at translational and transcriptional levels. We are conducting correlative biology studies in patient cohorts to determine whether a particular gene, protein, or metabolite contributes to progression free survival, overall survival, and toxicity.  

Current Research

Identifying Underlying Mechanisms of Radiation and Drug Resistance in Treatment Refractory Tumors

Short-circuiting signal transduction pathways for chemo- and radio- sensitization of tumors. Discovering molecular and gene signatures for radiation and chemotherapy synergism. References: J. Inorg. Biochem., 2012, 106(1), 32-42; Neuro-Oncology 2011,13, 22; Int J Radiat Oncol 2011;81: S753 and S704; AACR, 2011, TB 2478 and 2484, p 274.

Glioma Stem Cells

Identifying, isolating and targeting cancer stem cells to eradicate recurrent tumors. Developing models to Interrogate stem cell biology. References: Neuro-Oncology, 2009, 11(5), 679. Int J Radiat Oncol, 2009, 75(3), S545. AACR, 2009, TB 1080, p 166. Int J Radiat Oncol, 2008, 72(1), S53.

Exploiting Protein-Protein Interactions at Transcriptional and Translational Level and Identifying New Therapeutic Targets

Post-translational modifications, nuclear export signals, subcellular location and colocalization of proteins, homozygote and heterozygote deletions and functional characterization. References: AACR, 2011, TB 2484, p 274. Int J Radiat Oncol, 2009, 75(3), S68-S69. Neuro-Oncology 2008;10: 852

Integrative OMICS

Profiling Genomics, Transcriptomics, Epigenomics, Metabolomics and Proteomics on patient biopsies and identifying clusters associated with better and poor survival benefit and validating them for therapeutic benefit. Recently we have undertaken RadioOMICS profiling to identify potential therapeutic targets. References: AACR, 2011, TB 2504, p 275. Int J Radiat Oncol, 2010, 78(3), S657


  • National Institute of Technology, Ph.D.
  • Massachusetts General Hospital - Harvard Medical School, Postdoctoral.